MX2023002389A - Compuestos moduladores de gpr52. - Google Patents
Compuestos moduladores de gpr52.Info
- Publication number
- MX2023002389A MX2023002389A MX2023002389A MX2023002389A MX2023002389A MX 2023002389 A MX2023002389 A MX 2023002389A MX 2023002389 A MX2023002389 A MX 2023002389A MX 2023002389 A MX2023002389 A MX 2023002389A MX 2023002389 A MX2023002389 A MX 2023002389A
- Authority
- MX
- Mexico
- Prior art keywords
- gpr52
- modulator compounds
- formula
- receptors
- descriptions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Amplifiers (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2013558.8A GB202013558D0 (en) | 2020-08-28 | 2020-08-28 | GRP52 Modularor compounds |
| PCT/GB2021/052247 WO2022043714A1 (en) | 2020-08-28 | 2021-08-31 | Gpr52 modulator compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002389A true MX2023002389A (es) | 2023-05-03 |
Family
ID=72749711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002389A MX2023002389A (es) | 2020-08-28 | 2021-08-31 | Compuestos moduladores de gpr52. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230348416A1 (https=) |
| EP (1) | EP4204408A1 (https=) |
| JP (1) | JP7761635B6 (https=) |
| KR (1) | KR20230058132A (https=) |
| CN (1) | CN116507622B (https=) |
| AU (1) | AU2021330379A1 (https=) |
| BR (1) | BR112023003696A2 (https=) |
| CA (1) | CA3193487A1 (https=) |
| GB (1) | GB202013558D0 (https=) |
| IL (1) | IL301007B1 (https=) |
| MX (1) | MX2023002389A (https=) |
| WO (1) | WO2022043714A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206413A (zh) | 2020-04-22 | 2022-02-16 | 美商紐羅克里生物科學有限公司 | Gpr52調節劑及其使用方法 |
| WO2025117662A1 (en) * | 2023-11-29 | 2025-06-05 | Actio Biosciences, Inc. | Heterocyclic compounds useful as kcnt1 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180004193A (ko) * | 2015-04-29 | 2018-01-10 | 아레나 파마슈티칼스, 인크. | Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드 |
| JP6859358B2 (ja) * | 2015-11-02 | 2021-04-14 | ゲナーゼ セラピューティクス ベー．フェー．Ｇｅｎａｓｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｂ．Ｖ． | テトラヒドロインダゾール及びその医学的使用 |
| WO2021009003A1 (en) * | 2019-07-16 | 2021-01-21 | Universität Hamburg | Computer-based identification of types in the empirical sciences by tangle theory |
| CA3156474A1 (en) * | 2019-11-08 | 2021-05-14 | Heptares Therapeutics Limited | GPR52 MODULATING COMPOUNDS |
-
2020
- 2020-08-28 GB GBGB2013558.8A patent/GB202013558D0/en not_active Ceased
-
2021
- 2021-08-31 US US18/023,411 patent/US20230348416A1/en active Pending
- 2021-08-31 KR KR1020237010457A patent/KR20230058132A/ko active Pending
- 2021-08-31 IL IL301007A patent/IL301007B1/en unknown
- 2021-08-31 WO PCT/GB2021/052247 patent/WO2022043714A1/en not_active Ceased
- 2021-08-31 CN CN202180073276.0A patent/CN116507622B/zh active Active
- 2021-08-31 CA CA3193487A patent/CA3193487A1/en active Pending
- 2021-08-31 AU AU2021330379A patent/AU2021330379A1/en active Pending
- 2021-08-31 EP EP21769501.4A patent/EP4204408A1/en active Pending
- 2021-08-31 MX MX2023002389A patent/MX2023002389A/es unknown
- 2021-08-31 JP JP2023514050A patent/JP7761635B6/ja active Active
- 2021-08-31 BR BR112023003696A patent/BR112023003696A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7761635B6 (ja) | 2025-11-27 |
| EP4204408A1 (en) | 2023-07-05 |
| WO2022043714A1 (en) | 2022-03-03 |
| JP7761635B2 (ja) | 2025-10-28 |
| CN116507622A (zh) | 2023-07-28 |
| AU2021330379A1 (en) | 2023-03-30 |
| GB202013558D0 (en) | 2020-10-14 |
| IL301007A (en) | 2023-05-01 |
| KR20230058132A (ko) | 2023-05-02 |
| CN116507622B (zh) | 2026-02-24 |
| US20230348416A1 (en) | 2023-11-02 |
| CA3193487A1 (en) | 2022-03-03 |
| JP2023539336A (ja) | 2023-09-13 |
| BR112023003696A2 (pt) | 2023-04-04 |
| IL301007B1 (en) | 2026-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011333A (es) | Compuestos moduladores de gpr52. | |
| CL2019003126A1 (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| PE20221627A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
| MX2023011675A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
| UY38892A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| ECSP20029790A (es) | Compuestos moduladores de sting y métodos de elaboración y uso | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| MX2023000418A (es) | Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia. | |
| MX2023011715A (es) | Compuestos de oxoisoindolina sustituidos con piridinilo. | |
| MX2022013856A (es) | Moduladores htt para tratar la enfermedad de huntington. | |
| AR094553A1 (es) | Formas de oxadiazolpirazina | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| MX2023002389A (es) | Compuestos moduladores de gpr52. | |
| ECSP20080272A (es) | DERIVADOS DE TIOFENO PARA EL TRATAMIENTO DE TRASTORNOS CAUSADOS POR IgE | |
| CA3156474A1 (en) | GPR52 MODULATING COMPOUNDS | |
| MX2020009443A (es) | Método de modulación de las vías de señalización de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol. | |
| CR20200522A (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
| MX2020012940A (es) | Metodos de uso de moduladores de empalme. | |
| MX2020003185A (es) | Nuevos compuestos heterociclicos. | |
| MX2024002581A (es) | Lou064 para el tratamiento de la esclerosis multiple. | |
| MX2019004579A (es) | Composiciones para el cuidado bucal y metodos de uso. | |
| CL2024000742A1 (es) | Compuestos moduladores de gpr52 | |
| MX390507B (es) | Compuestos de amida y su uso. | |
| AR110770A1 (es) | Moduladores del canal de potasio |